Related Experiment Videos
Pathogenic mechanisms in membranoproliferative glomerulonephritis
Kelly D Smith1, Charles E Alpers
1Department of Pathology, University of Washington, Seattle, WA 98195, USA.
Current Opinion in Nephrology and Hypertension
|June 3, 2005
Summary
This review explores the pathogenesis of membranoproliferative glomerulonephritis (MPGN), a kidney disease linked to hepatitis C virus infection. New findings highlight the roles of innate immunity and complement activation in MPGN progression, suggesting potential therapeutic targets.
Area of Science:
- Nephrology
- Immunology
- Virology
Background:
- Membranoproliferative glomerulonephritis (MPGN) is a poorly understood glomerular injury.
- MPGN is the primary renal manifestation of hepatitis C virus (HCV) infection, a global pandemic.
- Growing attention is focused on understanding MPGN pathogenesis due to its association with HCV.
Purpose of the Study:
- To review new information on the pathogenesis of MPGN.
- To discuss the role of innate immunity and complement activation in MPGN.
- To identify potential therapeutic targets for MPGN.
Main Methods:
- Review of recent scientific literature.
- Description of murine models for MPGN pathogenesis studies.
- Analysis of evidence implicating innate immune mechanisms and complement activation.
Main Results:
- Recent evidence suggests innate immune mechanisms contribute to immune- and autoimmune-mediated glomerulonephritis.
- The alternative pathway of complement activation plays a role in amplifying glomerulonephritic injury.
- Murine models of MPGN are available for pathogenesis research.
Conclusions:
- Understanding complement activation and innate immunity in MPGN pathogenesis can lead to new therapeutic targets.
- Complement cascade inhibitors are under clinical investigation for glomerular diseases.
- Further research is needed to identify specific innate immune targets for MPGN treatment.